Navigation Links
Bacterial Skin and Skin Structure Infections Market: SSSI Pipeline Review, H2 2013 at ReportsnReports.com
Date:1/10/2014

Dallas, Texas (PRWEB) January 10, 2014

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review (http://www.reportsnreports.com/reports/271749-skin-and-skin-structure-infections-sssi-caused-by-bacteria-pipeline-review-h2-2013.html), Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.
  • A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=271749.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Inquire for Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=271749.

List of Tables
Number of Products Under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2013
Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
GlaxoSmithKline plc, H2 2013
Cubist Pharmaceuticals, Inc., H2 2013
Paratek Pharmaceuticals, Inc., H2 2013
Affinium Pharmaceuticals, Inc., H2 2013
MerLion Pharmaceuticals Pte Ltd, H2 2013
Nabriva Therapeutics AG, H2 2013
Cempra Pharmaceuticals, Inc., H2 2013
Tetraphase Pharmaceuticals Inc., H2 2013
Durata Therapeutics Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Drug Profile Updates
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2013
Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

Explore more reports from Global Markets Direct Market @ http://www.reportsnreports.com/publisher/global-markets-direct/ and Skincare Market.

About Us
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets.

Read the full story at http://www.prweb.com/releases/bacterial-skin-and-skin/structure-infections-sssi/prweb11478629.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pharmacy Robots Linked to Bacterial Contamination of Drugs
2. Children with juvenile arthritis have higher rates of bacterial infection
3. University of Minnesota startup to treat challenging bacterial infection
4. Fish Pedicure a Recipe for Bacterial Infection, Researchers Warn
5. Zooming in on bacterial weapons in 3-D
6. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
7. Study Ties Kids Allergy Risks to Antibacterials, Preservatives
8. Bacterial Vaginosis Increases Female-to-Male HIV Transmission Risk
9. New mechanism of bacterial pathogenesis discovered
10. AuCoin gets $600,000 to refine new test for deadly bacterial infection melioidosis
11. NIH uses genome sequencing to help quell bacterial outbreak in Clinical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology: